Call for Abstract

9th International Conference on Alzheimer’s Disease & Dementia, will be organized around the theme “ An Insight into Advanced Research and Diagnostic Approaches in Alzheimer’s Disease and Dementia”

Dementia 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Dementia 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Alzheimers disease
  • Track 1-2Post stroke dementia
  • Track 1-3Subcortical vascular dementia
  • Track 1-4Mixed dementia
  • Track 1-5Multi-infarct dementia
  • Track 1-6Young onset dementia
  • Track 1-7Sleep and dementia
  • Track 1-8White matter and dementia
  • Track 1-9Computational and Mathematical modelling of dementia
  • Track 1-10Stroke-related dementia
  • Track 1-11Treatment of Alzheimer’s Disease
  • Track 1-12Diagnosis of Alzheimer’s Disease
  • Track 1-13Parkinson dementia
  • Track 2-1Vascular dementia prognosis
  • Track 2-2Senile dementia
  • Track 2-3Senelity
  • Track 2-4Cognitive impairment
  • Track 2-5Advances in vascular dementia
  • Track 2-6Cognitive impairment treatment

 

 

 

  • Track 3-1Neurotrauma-treatment studies
  • Track 3-2Neurosurgery
  • Track 3-3Biomarkers of Traumatic Brain Injury
  • Track 3-4Emerging Neuromodulation Techniques
  • Track 3-5Neurorehabilitation
  • Track 3-6Neurotechnology clinical research
  • Track 3-7Acquired Brain Injury
  • Track 3-8Vascular Brain Injury
  • Track 3-9Epidemiology and prevention
  • Track 3-10Therapeutic Approaches to Brain Injury
  • Track 4-1Lewy body disorders
  • Track 4-2Muscle rigidity
  • Track 4-3Neurotransmitter abnormalities
  • Track 4-4Symptoms of lewy body dementia
  • Track 4-5Causes of lewy body dementia
  • Track 4-6Management of lewy body dementia
  • Track 4-7Advances in lewy body dementia research
  • Track 5-1Vascular dementia
  • Track 5-2Rehabilitation therapy: Dementia
  • Track 5-3Traumatic Brain Injury
  • Track 5-4Stroke Related Dementia
  • Track 5-5Mild cognitive impairment
  • Track 5-6Creutzfeldt-Jakob disease
  • Track 5-7Fronto-temporal dementia
  • Track 5-8Dementia with lewy bodies
  • Track 5-9Rehabilitation therapy: Stroke
  • Track 6-1Biomarkers
  • Track 6-2Novel approaches in biomarkers
  • Track 6-3Living with Alzheimer’s disease
  • Track 6-4Patient’s psychological changes
  • Track 6-5Neuropathology
  • Track 6-6Neuropsychology
  • Track 6-7Early detection possibilities
  • Track 6-8Different diagnosis procedures
  • Track 6-9New methods in diagnosis
  • Track 6-10Normal brain aging
  • Track 7-1Amyloid and Tau imaging
  • Track 7-2Imaging correlates of clinical and cognitive
  • Track 7-3Imaging animal models
  • Track 7-4New methods in imaging
  • Track 7-5Structural and functional MRI
  • Track 7-6Positron emission tomography
  • Track 7-7MR spectroscopy
  • Track 7-8EEG and brain mapping
  • Track 7-9SPECT imaging
  • Track 7-10Biomarker variables
  • Track 8-1Aging
  • Track 8-2Prions and Alzheimer’s disease
  • Track 8-3Cellular signaling and cell to cell transmission
  • Track 8-4Oxidative damage
  • Track 8-5Mitochondrial dysfunction
  • Track 8-6Autoimmunity in Alzheimer’s
  • Track 8-7Blood-brain barrier and transport
  • Track 8-8Neurogenesis and stem cells
  • Track 8-9Cell death
  • Track 9-1Neurodegenerative diseases
  • Track 9-2Geriatric emergency medicine
  • Track 9-3Geriatric diagnostics
  • Track 9-4Geriatric neurology
  • Track 9-5Geriatric oncology
  • Track 9-6Geriatric psychiatry or psychogeriatric
  • Track 9-7Geriatric pharmacotherapy
  • Track 9-8Alcohol addiction and mental health
  • Track 9-9Nutritional deficiency
  • Track 9-10Preventions: Mental activity and healthy lifestyle
  • Track 10-1Brain accumulation of toxic amyloid β (Aβ)
  • Track 10-2Amyloid Plaques & Neurofibrillary Tangles
  • Track 10-3Amyloid neuroimaging and biomarkers
  • Track 10-4Amyloidosis and Neurodegeneration
  • Track 10-5Aβ deposition, cognition and brain volume
  • Track 10-6The amyloid hypothesis and potential treatments
  • Track 11-1Education and training of medical professionals
  • Track 11-2Care and quality of life
  • Track 11-3Caregiver support
  • Track 11-4Person centered care
  • Track 11-5Cognitive training
  • Track 11-6Support and training for informal and professional carers
  • Track 11-7Putting scientific knowledge into practice
  • Track 11-8Non-pharmacological Interventions
  • Track 11-9Functional foods
  • Track 11-10Art, music and life style
  • Track 11-11Nursing and Care Practice
  • Track 12-1Abeta, truncated and pGlu-Abeta
  • Track 12-2Immunotherapy
  • Track 12-3Neurotransmitter-based targets
  • Track 12-4Anti-oxidants
  • Track 12-5Neurotrophic factors
  • Track 12-6Protein aggregation
  • Track 12-7Deep brain stimulation
  • Track 12-8Misfolding and chaperones
  • Track 12-9Gene therapy
  • Track 12-10Nanotechnology
  • Track 12-11Drug-delivery systems
  • Track 12-12Anti-inflammatory targets
  • Track 14-1Transgenic models
  • Track 14-2Pharmacological and lesion models
  • Track 14-3Natural and semi natural models
  • Track 14-4Primate models
  • Track 14-5Zebra fish models
  • Track 14-6Animal models of human cognitive aging
  • Track 14-7Development of new animal models
  • Track 14-8Genetics of translational models
  • Track 14-9Protein-protein interactions
  • Track 14-10Ethical issues with animal models